Table 2 Baseline demographic and disease characteristics of patients who achieved remission in the consecutive measurement

RF+, %

82.9

83.8

83.8

RF, average, IU/ml, mean (SD)

71.4 (100.2)

88.7 (189.0)

86.6 (183.3)

ESR, mm/h, mean (SD)

12.2 (8.5)

17.8 (14.4)

17.4 (13.9)

CRP, mg/L, mean (SD)

1.7 (3.9)

2.5 (8.4)

1.8 (4.0)

Measurement interval, mo., mean (SD)

12.2 (6.5)

12.4 (6.3)

12.4 (6.3)

MTX usage, %

61.3

61.9

61.4

MTX, mg, mean (SD)

7.6 (3.0)

7.5 (2.8)

7.5 (2.9)

Prednisolone usage, %

12.5

9.9

9.1

Prednisolone, mg, mean (SD)

4.1 (7.8)

4.7 (10.1)

4.5 (10.0)

bDMARD or tsDMARD usage, %

44.3

43.1

43.7

TNFα-i, %

23.7

25.8

26.5

IL6-i, %

18.6

10.3

10.1

CTLA4-Ig, %

3.8

6.4

6.4

JAK-i, %

0.1

0.6

0.7